重大事件即時報告 8-K 2026-07-10

LABSTYLE INNOVATIONS CORP總裁兼首席商務官無限期延長醫療休假

AI 繁中摘要

DarioHealth Corp.（納斯代克：DRIO）於2026年7月10日提交8-K表格，披露總裁兼首席商務官Steven Nelson的臨時醫療休假已延長至無限期。公司表示，Nelson先生的職責將由高級管理團隊成員分擔，以確保日常營運不受影響。目前沒有透露具體接任安排或時間表。

📌 重點總結：
- 申報類型：8-K（重大事件報告）
- 事件：高級管理層變動（休假延長）
- 涉及人員：Steven Nelson（總裁兼首席商務官）
- 生效日期：2026年7月10日
- 過渡安排：高級管理團隊接手相關職責

🔍 對投資者的潛在意義：
管理層關鍵人物長期休假可能短期內影響業務執行及投資者信心，尤其是銷售及商業戰略層面。不過公司未下調業績指引，亦無提及營運出現重大中斷。投資者宜留意後續是否有正式接任公告或季度業績中對管理層變動的影響說明。

沒有其他財務數據或展望細節需要補充。

展開英文正文

false
 0001533998
 
 
 
 
 
 
 
 0001533998
 
 
 2026-07-10
 2026-07-10
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date
of Earliest Event Reported): July 10, 2026 

 

DARIOHEALTH CORP.

(Exact name of registrant as specified in its charter)

 

 
 Delaware 
 001-37704 
 45-2973162

 
 (State or other jurisdiction 

of incorporation) 
 (Commission

 File Number) 
 (IRS Employer

 Identification No.)

 

 

322 W 57th St., #33B 

New
York, New York 10019 (Address of Principal Executive Offices)

 

972- 4-770-6377 

(Issuer’s telephone
number)

 

(Former name or former
address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

 
 ¨
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
 

 
 ¨
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
 

 
 ¨
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
 

 
 ¨
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities registered pursuant to Section 12(b)
of the Act:

 

 
 Title of each class
  
 Trading
Symbol(s)
  
 Name of exchange on which 

registered

 
 Common Stock, par value $0.0001 per share
  
 DRIO
  
 The Nasdaq Capital Market LLC

 
 

Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth
company ¨

 

If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

  

  

 

 

 
 Item 5.02
 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 
 

On July 10, 2026, the
temporary medical leave of absence of Steven Nelson, President and Chief Commercial Officer of DarioHealth Corp., or the Company, was
extended for an indefinite period. During Mr. Nelson’s leave of absence, his responsibilities are being assumed by members
of the Company’s senior management team.

 

  

  

 

 

SIGNATURES

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

 

 
 Dated: July 10, 2026
 DARIOHEALTH CORP.

 
  
  

 
  
 By:
 /s/ Chen Franco-Yehuda

 
  
 Name:
  Chen Franco-Yehuda

 
  
 Title:
 Chief Financial Officer, Treasurer and Secretary